Aquestive Therapeutics (AQST) Operating Leases: 2020-2025
Historic Operating Leases for Aquestive Therapeutics (AQST) over the last 6 years, with Sep 2025 value amounting to $5.1 million.
- Aquestive Therapeutics' Operating Leases fell 8.62% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 8.62%. This contributed to the annual value of $5.0 million for FY2024, which is 7.98% down from last year.
- Latest data reveals that Aquestive Therapeutics reported Operating Leases of $5.1 million as of Q3 2025, which was down 2.46% from $5.2 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Operating Leases peaked at $6.0 million during Q1 2023, and registered a low of $1.9 million during Q4 2021.
- In the last 3 years, Aquestive Therapeutics' Operating Leases had a median value of $5.6 million in 2024 and averaged $5.5 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Operating Leases plummeted by 31.62% in 2021, and later skyrocketed by 168.80% in 2023.
- Over the past 5 years, Aquestive Therapeutics' Operating Leases (Quarterly) stood at $1.9 million in 2021, then skyrocketed by 161.31% to $5.1 million in 2022, then climbed by 6.18% to $5.4 million in 2023, then decreased by 7.98% to $5.0 million in 2024, then declined by 8.62% to $5.1 million in 2025.
- Its Operating Leases was $5.1 million in Q3 2025, compared to $5.2 million in Q2 2025 and $5.4 million in Q1 2025.